Dual Hormone Peptide Survodutide Reverses Liver Disease in Phase 2 Trial

Survodutide achieved MASH improvement without fibrosis worsening in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) of participants vs 14% on placebo (P<0.001). Liver fat reduction ≥30% occurred in 57-67% of survodutide groups vs 14% placebo. Fibrosis improved by ≥1 stage in 34-36% vs 22% placebo.

Phase 2, randomized, double-blind, placebo-controlled trial. 293 adults with biopsy-confirmed MASH and fibrosis (F1-F3) randomized 1:1:1:1 to survodutide 2.4 mg, 4.8 mg, 6.0 mg, or placebo via weekly subcutaneous injection for 48 weeks (24-week dose escalation + 24-week maintenance). Primary endpoint: histologic MASH improvement without fibrosis worsening.

MASH affects millions worldwide and has limited treatment options. Dual receptor agonism combining glucagon's fat-burning effects with GLP-1's metabolic benefits may offer a more powerful approach than GLP-1 alone, potentially changing how we treat this progressive liver disease.

This trial demonstrates that combining two peptide hormone pathways (glucagon + GLP-1) may be superior to single-pathway approaches for liver disease. It represents the broader trend of multi-target peptide therapeutics and could reshape treatment of the growing MASH epidemic.

Phase 2 trial — still needs phase 3 confirmation with larger numbers. The 6.0 mg dose unexpectedly performed worse than 4.8 mg, possibly due to tolerability-driven dropouts. High rates of GI side effects (nausea 66%, diarrhea 49%, vomiting 41%). 48-week duration may not capture long-term safety or sustained benefit.